Literature DB >> 21221875

Parkin gene alterations in ovarian carcinoma from northern Indian population.

Syed Jafar Mehdi1, Asgar Ali, M Moshahid Alam Rizvi.   

Abstract

Parkin, a tumor suppressor gene located on chromosome 6q25-27, has been identified as a target for mutation in many human malignancies like breast, ovaries, cervical and lungs etc. After a preliminary report on the loss of heterozygosity and altered Parkin expression in breast and ovarian tumors, we aimed to study loss of heterozygosity in the Parkin gene associated microsatellite markers and its expression in human ovarian cancer patients from Indian population. We examined 102 paired normal and ovarian cancer samples for allelic loss in Parkin gene locus using Parkin gene associated microsatellite markers through loss of heterozygosity and changes in its expression through semiquantitative RT-PCR. Loss of heterozygosity identified common region of loss in Parkin locus with highest frequency for the intragenic marker D6S1599 (53%) whereas, 49 of 102 (48%) specimens showed decreased or no expression of Parkin in ovarian tumors. The study revealed that presence of loss of heterozygosity was significantly higher in both the intragenic markers (D6S1599 and D6S305) as compared with the locus of flanking region (D6S1008) with their p value 0.000001 and 0.00008, respectively. It also revealed that Parkin inactivation is probably a combination of loss of heterozygosity coupled with downregulation of Parkin gene through an alternative means like epigenetic mechanism. These data strongly supports the previous study and argue that Parkin is a tumor suppressor gene whose inactivation may play an important role in ovarian carcinoma.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21221875     DOI: 10.1007/s12253-010-9351-x

Source DB:  PubMed          Journal:  Pathol Oncol Res        ISSN: 1219-4956            Impact factor:   3.201


  34 in total

1.  Chromosomal gains and losses in primary cutaneous melanomas detected by comparative genomic hybridization.

Authors:  B C Bastian; P E LeBoit; H Hamm; E B Bröcker; D Pinkel
Journal:  Cancer Res       Date:  1998-05-15       Impact factor: 12.701

2.  3 distinct regions of chromosome-6 are targets of loss of heterozygosity in human ovarian carcinomas.

Authors:  M Wan; S Zweizig; G Dablaing; J Zheng; M Velicescu; L Dubeau
Journal:  Int J Oncol       Date:  1994-11       Impact factor: 5.650

3.  Cancer statistics, 1998.

Authors:  S H Landis; T Murray; S Bolden; P A Wingo
Journal:  CA Cancer J Clin       Date:  1998 Jan-Feb       Impact factor: 508.702

4.  Allele loss on chromosome arm 6q and fine mapping of the region at 6q27 in epithelial ovarian cancer.

Authors:  I E Cooke; A N Shelling; V G Le Meuth; M L Charnock; T S Ganesan
Journal:  Genes Chromosomes Cancer       Date:  1996-04       Impact factor: 5.006

5.  Loss of heterozygosity at 6q is frequent and concurrent with 3p loss in sporadic and familial capillary hemangioblastomas.

Authors:  Sebsebe Lemeta; Lea Pylkkänen; Markku Sainio; Mika Niemelä; Sirkku Saarikoski; Kirsti Husgafvel-Pursiainen; Tom Böhling
Journal:  J Neuropathol Exp Neurol       Date:  2004-10       Impact factor: 3.685

6.  Alterations of the tumor suppressor gene Parkin in non-small cell lung cancer.

Authors:  Maria Cristina Picchio; Eric Santos Martin; Rossano Cesari; George Adrian Calin; Sai Yendamuri; Tamotsu Kuroki; Francesca Pentimalli; Manuela Sarti; Kristine Yoder; Larry R Kaiser; Richard Fishel; Carlo Maria Croce
Journal:  Clin Cancer Res       Date:  2004-04-15       Impact factor: 12.531

7.  Somatic mutations of the Parkinson's disease-associated gene PARK2 in glioblastoma and other human malignancies.

Authors:  Selvaraju Veeriah; Barry S Taylor; Shasha Meng; Fang Fang; Emrullah Yilmaz; Igor Vivanco; Manickam Janakiraman; Nikolaus Schultz; Aphrothiti J Hanrahan; William Pao; Marc Ladanyi; Chris Sander; Adriana Heguy; Eric C Holland; Philip B Paty; Paul S Mischel; Linda Liau; Timothy F Cloughesy; Ingo K Mellinghoff; David B Solit; Timothy A Chan
Journal:  Nat Genet       Date:  2009-11-29       Impact factor: 38.330

8.  Homozygous deletion on chromosome 9p and loss of heterozygosity on 9q, 6p, and 6q in primary human small cell lung cancer.

Authors:  A Merlo; E Gabrielson; M Mabry; R Vollmer; S B Baylin; D Sidransky
Journal:  Cancer Res       Date:  1994-05-01       Impact factor: 12.701

9.  Characterization of FRA6E and its potential role in autosomal recessive juvenile parkinsonism and ovarian cancer.

Authors:  Stacy R Denison; Gwen Callahan; Nicole A Becker; Leslie A Phillips; David I Smith
Journal:  Genes Chromosomes Cancer       Date:  2003-09       Impact factor: 5.006

10.  Multiple regions of chromosome 6q affected by loss of heterozygosity in primary human breast carcinomas.

Authors:  Z M Sheng; A Marchetti; F Buttitta; M H Champeme; D Campani; M Bistocchi; R Lidereau; R Callahan
Journal:  Br J Cancer       Date:  1996-01       Impact factor: 7.640

View more
  6 in total

1.  Implication of alterations in Parkin gene among North Indian patients with colorectal cancer.

Authors:  Raj Ranjan Tiwari; Khushnuma Wahabi; Ahmad Perwez; Zafar Iqbal Bhat; Syed Shamimul Hasan; Sundeep Singh Saluja; Moshahid Alam Rizvi
Journal:  Turk J Gastroenterol       Date:  2020-03       Impact factor: 1.852

2.  Implication of androgen receptor in urinary bladder cancer: a critical mini review.

Authors:  Arshad H Rahmani; Mohammad Alzohairy; Ali Yousif Y Babiker; Amjad A Khan; Salah M Aly; Moshahid A Rizvi
Journal:  Int J Mol Epidemiol Genet       Date:  2013-09-12

3.  Expressional analysis of p16 and cytokeratin19 protein in the genesis of oral squamous cell carcinoma patients.

Authors:  Ali Yousif Babiker; Arshad H Rahmani; Mohamed S Abdalaziz; Aqel Albutti; Salah M Aly; Hussain Gadelkareem Ahmed
Journal:  Int J Clin Exp Med       Date:  2014-06-15

Review 4.  Mitophagy in Cancer: A Tale of Adaptation.

Authors:  Monica Vara-Perez; Blanca Felipe-Abrio; Patrizia Agostinis
Journal:  Cells       Date:  2019-05-22       Impact factor: 6.600

5.  Parkin gene mutations are not common, but its epigenetic inactivation is a frequent event and predicts poor survival in advanced breast cancer patients.

Authors:  Khushnuma Wahabi; Ahmad Perwez; Shabeena Kamarudheen; Zafar Iqbal Bhat; Anurag Mehta; M Moshahid A Rizvi
Journal:  BMC Cancer       Date:  2019-08-20       Impact factor: 4.430

6.  High Inflammatory Tendency Induced by Malignant Stimulation Through Imbalance of CD28 and CTLA-4/PD-1 Contributes to Dopamine Neuron Injury.

Authors:  Li Dong; Yu-Min Zheng; Xiao-Guang Luo; Zhi-Yi He
Journal:  J Inflamm Res       Date:  2021-06-10
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.